Skip to main content
SpringerLink
Log in

Changing Views on the Treatment of Glomerulonephritis

  • Chapter
International Yearbook of Nephrology 1991

Part of the book series: International Yearbook of Nephrology 1991 ((IYNE,volume 3))

  • 44 Accesses

Abstract

Few would disagree that present treatments for glomerulonephritis (GN) are unsatisfactory. Rational approaches to treatment need to be based on a proper understanding of pathogenesis, together with knowledge of the factors that influence the severity of initial injury and the vigour of subsequent scarring. Unfortunately such information is lacking in the case of nephritis, and empiricism provides the only alternative.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lindemann W: Sur la mode d’action de certains poisons renaux. Ann Inst Pasteur, 14: 49–59, 1900.

    CAS  Google Scholar 

  2. Mellors RC, Ortega LG, Hollman HR: Role of gamma globulin in the pathogenesis of the renal lesions in systemic lupus erythematosus and chronic membranous glomerulonephritis with observations on the lupus cell reaction. J Exp Med, 106: 191–199, 1957.

    Article  PubMed  CAS  Google Scholar 

  3. Kniker WT, Cochrane CG: Pathogenic factors in vascular lesions of experimental serum sickness. J Exp Med, 122: 83, 1965.

    Article  PubMed  CAS  Google Scholar 

  4. Neale TJ, Tipping PG, Carson SD, Holdsworth SR: Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet, II: 421424, 1988.

    Google Scholar 

  5. Nolasco FEB, Cameron JS, Hartley B, Coelho A, Hildreth G, Reuben R: Intraglomerular T cells in nephritis: study with monoclonal antibodies. Kidney Int, 31: 1160–1166, 1987.

    Article  PubMed  CAS  Google Scholar 

  6. Rees AJ: The proliferation of glomerular cells. In: “Glomerulonephritis” GD Catto (Ed), Kluwer Academic Publishers, Lancaster, 1990.

    Google Scholar 

  7. Oliveira DBG, Peters DK: Autoimmunity and the kidney. Kidney Int, 35: 923–928, 1989.

    Article  PubMed  CAS  Google Scholar 

  8. Volhard F, Fahr T: Die Brightsche Nierenkrankheit. Springer, Berlin, 1914.

    Google Scholar 

  9. Ellis A: Natural history of Bright’s disease. Clinical, histological and experimental observations. Lancet, I: 34–36, 1942.

    Article  Google Scholar 

  10. Scheer RL, Grossman MA: Immune aspects of the glomerulonephritis associated with pulmonary haemorrhage. Ann Intern Med, 60:1009–1021, 1964.

    Google Scholar 

  11. Ortega LG, Mellors RC: Analytical pathology. IV. The role of localised antibodies in the pathogenesis of nephrotoxic nephritis in the rat. J Exp Med, 104: 151–170, 1956.

    Article  PubMed  CAS  Google Scholar 

  12. Hind CR, Lockwood CM, Peters DK, Paraskevakou H, Evans DJ, Rees AJ: Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet, I: 263–266, 1983.

    Article  Google Scholar 

  13. Heptinstall RH: Schonlein-Henoch syndrome; lung haemorrhage and glomerulonephritis, or Goodpasture’s syndrome. In: “Pathology of the Kidney”, Little, Brown & Co., Boston, 1990, pp 741–792.

    Google Scholar 

  14. McPhaul JJ Jr, Mullins JD: Glomerulonephritis mediated by antibody to glomerular basement membrane: Immunological, clinical and histopathological characteristics. J Clin Invest, 57: 351–361, 1976.

    Article  PubMed  Google Scholar 

  15. Donaghy M, Rees AJ: Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet, II: 1390–1393, 1983.

    Article  Google Scholar 

  16. Jennings L, Roholt OA, Pressman D, Blaum M, Andres GA, Brentjens JR: Experimental antialveolar basement membrane antibody-mediated pneumonitis. I. The role of increased permeability of the alveolar capillary wall induced by oxygen. J Immunol, 127: 129–134, 1981.

    PubMed  CAS  Google Scholar 

  17. Downie GM, Roholt OA, Jennings L, Blau M, Brentjens JR, Andres GA: Experimental antialveolar basement membrane antibody-mediated pneumonitis. II. Role of endothelial damage and repair, induction of autologous phase, and kinetics of antibody deposition in Lewis rats. J Immunol, 129: 2647–2652, 1982.

    PubMed  CAS  Google Scholar 

  18. Rees AJ, Peters DK, Compston DAS, Batchelor JR: Strong association between HLA DRw2 and antibody mediated Goodpasture’s syndrome. Lancet, I:966–968, 1978.

    Article  Google Scholar 

  19. Rees AJ, Demaine AG, Welsh KI: The association between immunoglobulin allotypes with auto-antibodies to glomerular basement membrane and their titre. Hum Immunol, 10: 213–221, 1984.

    Article  PubMed  CAS  Google Scholar 

  20. Benoit FL, Rulon CB, Theil GB, Doolan PD, Watten RH: Goodpasture’s syndrome. A clinicopathologic entity. Am J Med, 37: 424–444, 1964.

    CAS  Google Scholar 

  21. Wilson CB, Smith RC: Goodpasture’s syndrome associated with influenza A2 virus infection. Ann Intern Med, 76: 91–94, 1972.

    PubMed  CAS  Google Scholar 

  22. Rees AJ, Lockwood CM, Peters DK: Enhanced allergic tissue injury in Goodpasture’s syndrome by intercurrent bacterial infection. Br Med J, 2: 723–736, 1977.

    Article  CAS  Google Scholar 

  23. Heale WF, Matthiesson AM, Niall JF: Lung haemorrhage and nephritis (Goodpasture’s syndrome). Med J Aust, 2: 355–357, 1969.

    PubMed  CAS  Google Scholar 

  24. Beirne GJ, Brennan JT: Glomerulonephritis associated with hydrocarbon solvents. Arch Environ Health, 25: 365–369, 1972.

    PubMed  CAS  Google Scholar 

  25. Lemer RA, Glassock RJ, Dixon FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med, 126: 989–1004, 1967.

    Article  Google Scholar 

  26. Unanue ER, Dixon FJ: Experimental glomerulonephritis: Immunological events and pathogenetic mechanisms. Adv Immunol, 6: 1–90, 1967.

    Article  PubMed  CAS  Google Scholar 

  27. Huland H: Kasuistischer beitrag zur atiologie des Goodpasture-syndroms. Med Klin, 68: 437, 1973.

    PubMed  Google Scholar 

  28. van Zyl Smit R, Rees AJ, Peters DK: Factors affecting the severity of injury during nephrotoxic nephritis in rabbits. Clin Exp Immunol, 54: 366–372, 1983.

    PubMed  Google Scholar 

  29. Naish PF, Thomson NM, Simpson IJ, Peters DK: Role of polymorphonuclear leucocytes in the autologous phase of nephrotoxic nephritis. Clin Exp Immunol, 22: 102–111, 1975.

    PubMed  CAS  Google Scholar 

  30. Tomosugi NI, Cashman SJ, Hay H, Pusey CD, Evans DJ, Shaw A, Rees AJ: Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumour necrosis factor, and interleukin-1. J Immunol, 142: 3083–3090, 1989.

    PubMed  CAS  Google Scholar 

  31. El Nahas AM, Lechler R, Zoob SN, Rees AJ: Progression to renal failure after nephrotoxic nephritis in rats studied by renal transplantation. Clin Sci, 68: 15–21, 1985.

    PubMed  Google Scholar 

  32. Johnson JP, Whitman W, Briggs WA, Wilson CB: Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture’s syndrome. Am J Med, 64: 354–359, 1978.

    Article  PubMed  CAS  Google Scholar 

  33. Peters DK, Rees AJ, Lockwood CM, Pusey CD: Treatment and prognosis in antibasement membrane antibody mediated nephritis. Transplant Proc, 14: 513–521, 1982.

    PubMed  CAS  Google Scholar 

  34. Pusey CD, Lockwood CM: Plasma exchange for glomerular disease. In: “Nephrology”, RR Robinson (Ed), Springer-Verlag, New York, 1984, pp 1474–1485.

    Google Scholar 

  35. Savage COS, Pusey CD, Bowman C, Rees AJ, Lockwood CM: Antiglomerular basement membrane antibody mediated disease in the British Isles 1980–4. Br Med J, 292: 301–304, 1986.

    Article  CAS  Google Scholar 

  36. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med, 318: 1657–1666, 1988.

    Article  PubMed  CAS  Google Scholar 

  37. Saus J, Wieslander J, Langeveld JPM, Quinones S, Hudson BG: Identification of the Goodpasture antigen as the A3 (IV) chain of collagen IV. J Biol Chem, 263: 13374–13380, 1988.

    PubMed  CAS  Google Scholar 

  38. Pressey A, Pusey CD, Dash A, Peters DK, Lockwood CM: Production of a monoclonal antibody to autoantigenic components of human glomerular basement membrane. Clin Exp Immunol, 54: 178–184, 1983.

    PubMed  CAS  Google Scholar 

  39. Bygren P, Freiburghaus C, Lindholm T, Simonsen O, Thysell H, Wieslander J: Goodpasture’s syndrome treated with staphylococcal protein A immunoadsorption. Lancet, II: 1295–1296, 1985.

    Article  Google Scholar 

  40. Salant DJ: Nephrology forum: immunopathogenesis of crescentic glomerulonephritis and lung purpura. Kidney Int, 32: 408–425, 1987.

    Article  PubMed  CAS  Google Scholar 

  41. Van der Woude FJ, Daha MR, Van Es LA: The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol, 78: 143–148, 1989.

    PubMed  Google Scholar 

  42. Abbott F, Jones SJ, Lockwood CM, Rees AJ: Autoantibodies to glomerular antigens in patients with Wegener’s granulomatosis. Nephrol Dial Transplant, 4: 1–8, 1989.

    PubMed  CAS  Google Scholar 

  43. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med, 98: 76–85, 1983.

    PubMed  CAS  Google Scholar 

  44. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol, 9: 368–375, 1989.

    Article  PubMed  CAS  Google Scholar 

  45. Couser WG: Idiopathic rapidly progressive glomerulonephritis. Am J Nephrol, 2: 57–69, 1982.

    Article  PubMed  CAS  Google Scholar 

  46. International study of kidney disease in children: Nephrotic syndrome: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int, 13: 159–165, 1978.

    Google Scholar 

  47. Cameron JS, Turner DR, Ogg CS, Sharpsone P, Brown CB: The nephrotic syndrome in adults with “minimal change glomerular lesion”. Q J Med, 43: 461–488, 1974.

    PubMed  CAS  Google Scholar 

  48. Khokhar N, Akavaram NR, Quinones EM: Lipoid nephrosis in the elderly. South Med J, 73: 790–791, 1980.

    Article  CAS  Google Scholar 

  49. Morel-Maroger Striker L, Striker GE: Glomerular Lesions in malignancies. Contr Nephrol, 48: 111–122, 1985.

    Google Scholar 

  50. Eagen JW, Lewis EJ: Glomerulopathies of neoplasia. Kidney Int, 11: 297–303, 1977.

    Article  PubMed  CAS  Google Scholar 

  51. Plager J, Stutzman L: Acute nephrotic syndrome as a manifestation of active Hodgkin’s disease. Report of four cases and review of the literature. Am J Med, 50: 56–66, 1971.

    Article  PubMed  CAS  Google Scholar 

  52. Hyman LR, Burkholder PM, Joo PA: Malignant lymphoma and nephrotic syndrome. A clinicopathologic analysis with light, immunofluorescence and electron microscopy of the renal lesion. J Pediatr, 82: 207–212, 1973.

    Article  PubMed  CAS  Google Scholar 

  53. Shalhoub RJ: Pathogenesis of lipoid nephrosis: a disorder of T cell function. Lancet, II: 556–560, 1974.

    Article  Google Scholar 

  54. Cornfeld D, Schwartz MW: Nephrosis: a long-term study of children treated with corticosteroids. J Pediatr, 68: 507–515, 1966.

    Article  Google Scholar 

  55. International study of kidney disease in children: The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr, 98: 561–564, 1981.

    Article  Google Scholar 

  56. Grupe WE: Childhood nephrotic syndrome: clinical associations and response to therapy. Postgrad Med, 65: 229–231, 1979.

    PubMed  CAS  Google Scholar 

  57. Hoyer JR: Idiopathic nephrotic syndrome with minimal glomerular changes. In: “Contemporary Issues in Nephrology”, BM Brenner and JH Stein (Eds), Churchill Livingstone, New York, 1982, p 145.

    Google Scholar 

  58. Zech P, Colon S, Pointet P, Deteix P, Labeeuw M, Leitienne P: The nephrotic syndrome in adults aged over 60: etiology, evolution, and treatment of 76 cases. Clin Nephrol, 17: 232–236, 1982.

    PubMed  CAS  Google Scholar 

  59. Barratt TM, Soothill JF: Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet, II: 479–482, 1970.

    Article  Google Scholar 

  60. International study of kidney disease in children: Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Lancet, II: 423–427, 1974.

    Google Scholar 

  61. Williams SA, Makker SP, Inglefinger JR: Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. N Engl J Med, 302: 929, 1980.

    Article  PubMed  CAS  Google Scholar 

  62. Tejani AT, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR: Cyclosporineinduced remission of relapsing nephrotic syndrome in children. Kidney Int, 33: 729–734, 1988. 91

    Article  PubMed  CAS  Google Scholar 

  63. Trompeter RS, Evans PR, Barratt TM: Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet, I: 1177–1179, 1981.

    Article  Google Scholar 

  64. Coggins CH, Frommer JP, Glassock RJ: Membranous nephropathy. Sem Nephrol, 2: 264–273, 1982.

    Google Scholar 

  65. Jacobs C, Brunner FP, Chantier C, Donckerwolcke RA, Gerland HJ, Hathway RA, Selwood NH, Wing AJ: Combined report on regular dialysis and transplantation in Europe, VII 1976. Proc EUR Dial Transplant Assoc, 14: 3–69, 1977.

    PubMed  CAS  Google Scholar 

  66. Disney APS: Ninth Report of the Australian and New Zealand Combined Dialysis and Transplantation Registry. Queen Elizabeth Hospital, Woodville, South Australia, 1986.

    Google Scholar 

  67. Ehrenreich T, Churg J: Pathology of membranous nephropathy. In: “Pathology Annual”, SC Sommers (Ed), Appleton-Century-Crofts, New York, 1968, pp 145–186.

    Google Scholar 

  68. Klouda PT, Manos J, Acheson EJ, Dyer PA, Goldby FS, Harris R, Lawler W, Mallick NP, Williams G: Strong association between idiopathic membranous nephropathy and HLA-DRw3. Lancet, II: 770–771, 1979.

    Article  Google Scholar 

  69. Garovoy MR: Idiopathic membranous glomerulonephritis: an HLA-associated disease. In: “Histocompatibility Testing 1980”, PI Terasaki (Ed), UCLA, Los Angeles, 1980, pp 673–680.

    Google Scholar 

  70. Tomura S, Kashiwabara H, Tuchida H, Shishido H, Sakurai S, Miyajima T, Tsuji K, Takeuchi J: Strong association of idiopathic membranous nephropathy with HLA-DR2 and MT1 in Japanese. Nephron, 36: 242–245,1984.

    Article  PubMed  CAS  Google Scholar 

  71. Hassan AA, Le Petit JC, Berthoux FC: Immunogenetics of membranous glomerulonephritis. Kidney Int, 32: 606,1987 (Abstract).

    Google Scholar 

  72. Stenglein B, Thoenes GH, Günther E: Genetically controlled autologous immune complex glomerulonephritis in rats. J Immunol, 115: 895–897,1975.

    PubMed  CAS  Google Scholar 

  73. Stenglein B, Thoenes GH, Günther E: Genetic control of susceptibility to autologous immune complex glomerulonephritis in inbred rat strains. Clin Exp Immunol, 33: 88–94, 1978.

    PubMed  CAS  Google Scholar 

  74. Heymann W, Hackel DB, Harwood S, Wilson SGF, Hunter JLP: Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspension. Proc Soc Exp Biol Med, 100: 660–664, 1959.

    PubMed  CAS  Google Scholar 

  75. van Damme BJC, Fleuren GJ, Bakker WW, Vernier RL, Hoedemaeker PHJ: Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest, 38: 502–510, 1978.

    Google Scholar 

  76. Neale TJ, Couser WG, Salant DJ, Lowenstein LM, Wilson CB: Specific uptake of Heymann’s nephritic kidney eluate by rat kidney. Studies in vivo and in isolated perfused kidneys. Lab Invest, 46: 450–453, 1982.

    CAS  Google Scholar 

  77. Niles J, Collins B, Baird L, Erikson M, Bradford D, Pan G, Hsiung CK, Schneeberger E, Bhan A, McCluskey R: Antibodies reactive with a renal glycoprotein and with deposits in membranous nephritis. Kidney Int, 31: 338, 1987 (Abstract).

    Google Scholar 

  78. Kerjaschki D: In Nephrology Forum: Kinetics of immune deposits in membranous nephropathy. Kidney Int, 35: 1418–1428, 1989.

    Article  Google Scholar 

  79. Mathieson PW, Rees AJ: A critical review of treatment for membranous nephropathy. In: “Advances in Nephrology”, J-P Grunfeld, JF Bach, J-L Funck-Brentano and MH Maxwell (Eds), Year Book Medical Publishers, Inc, Chicago, London, Boca Raton, 1990

    Google Scholar 

  80. Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C: Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant, 4: 525–529, 1989.

    PubMed  CAS  Google Scholar 

  81. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med, 301: 1301–1306, 1979.

    Article  Google Scholar 

  82. Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med, 320: 210–215, 1989.

    Article  PubMed  CAS  Google Scholar 

  83. Cameron JS, Healy MJR, Adu D: The Medical Research Council trial of short-term high dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med, 274: 133–156, 1990.

    Google Scholar 

  84. Lagrue G, Bernard D, Bariety J, Druet P, Guenel J: Traitement par le chlorambucil et l’azathioprine dans les glomerulonephrites primitives. Resultats d'une etude “controllee”. J Urol Nephrol, 9: 655–672, 1975.

    Google Scholar 

  85. Donadio JV Jr, Holley KE, Anderson CF, Taylor WF: Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int, 6: 431–439,1974.

    Article  PubMed  Google Scholar 

  86. Suki WN, Chavez A: Membranous nephropathy: response to steroids and immunosuppression. Am JNephrol, 1: 11–16, 1981.

    Article  CAS  Google Scholar 

  87. West ML, Jindal KK, Bear RA, Goldstein MB: A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney Int, 32: 579–584, 1987.

    Article  PubMed  CAS  Google Scholar 

  88. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Poxxi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F: Controlled trial of methyl prednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med, 310:946–950, 1984.

    Article  PubMed  CAS  Google Scholar 

  89. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sasdelli M, Locatelli F: A randomized trial of methyl-prednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med, 320: 8–13, 1989.

    Article  PubMed  CAS  Google Scholar 

  90. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med, 304:441–447, 1981.

    Article  PubMed  CAS  Google Scholar 

  91. Patapanian H, Graham S, Sambrook PN, Browne CD, Champion GD, Cohen ML, Day RO: The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol, 27:44–47, 1988.

    Article  PubMed  CAS  Google Scholar 

  92. Donadio JVJr, Tones VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu C-P: Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int, 33: 708–715,1988.

    Article  PubMed  Google Scholar 

  93. Mathieson PW, Turner AN, Maidment CGH, Evans DJ, Rees AJ: Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet, II: 869–872, 1988.

    Article  Google Scholar 

  94. Short CD, Solomon LR, Gokal R, Mallick NP: Methlprednisolone in patients with membranous nephropathy and declining renal function. Q J Med, 247: 929–940, 1987.

    Google Scholar 

  95. Williams PS, Bone JM: Immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis. Nephrol Dial Transplant, 4: 181–186, 1989.

    PubMed  CAS  Google Scholar 

  96. Schena FP, Cameron JS: Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey. Am J Med, 85: 315–326, 1988.

    Article  PubMed  CAS  Google Scholar 

  97. McEnery PT, McAdams AJ, West CD: The effect of prednisone in a high-dose, alternate-day regimen in the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine, 64: 401–424,1986.

    Google Scholar 

  98. International study of kidney disease in children: Alternate day steroid therapy in membranoproliferative glomerulonephritis: a randomised controlled clinical trial. Kidney Int, 21: 150, 1982.

    Google Scholar 

  99. Donadio JV, Anderson CF, Mitchell JC III: Membranoproliferative glomerulonephritis: a prospective trial of platelet inhibitor therapy. N Engl J Med, 310:1421–1426, 1984.

    Article  PubMed  Google Scholar 

  100. Cameron JS: Treatment of primary glomerulonephritis using immunosuppressive agents. Am J Nephrol, 9 (Suppl 1): 33–40, 1989.

    Article  PubMed  Google Scholar 

  101. Trompeter RS: Steroid resistant nephrotic syndrome: a review of the treatment of focal segmental glomerulosclerosis (FSGS) in children. In: “Recent Advances in Paediatric Nephrology”, K Murakami, T Kitagawa and K Yabuta (Eds), Excerpia Medica, Amsterdam, 1987, pp 363–371.

    Google Scholar 

  102. A report of the International Study of Kidney Disease in Children: Cyclophosphamide therapy in focal segmental glomerulosclerosis: a controlled clinical trial. Eur J Paediat, 140: 149, 1983 (Abstract).

    Google Scholar 

  103. Brodehl J, Hoyer PF, Oemar BS, Helmchen U, Wonigeit K: Cyclosporine treatment of nephrotic syndrome in children. Transplant Proc, 20 (Suppl 4): 269–274, 1988.

    PubMed  CAS  Google Scholar 

  104. Meyrier A: Treatment with cyclosporin of patients with idiopathic nephrotic syndrome. Springer Semin Immunopathol, 9: 441–450, 1987.

    Article  PubMed  CAS  Google Scholar 

  105. Kobayashi Y, Fujii K, Hiki Y: Steroid therapy in IgA nephropathy. A prospective pilot study in moderate proteinuric cases. Q J Med, 61: 935–943, 1986.

    CAS  Google Scholar 

  106. Lai KN, Lai FM-M, Li PKT, Vallance-Owen J: Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J, 295: 1165–1168, 1987.

    Article  CAS  Google Scholar 

  107. Sandimmune (E) (ciclosporin) in Autoimmune Diseases. A Selection of Publications. Med. Documentation Sandoz, Basle, 1989.

    Google Scholar 

  108. Starzl TE, Todo S, Fung J, Demelris AJ, Venkataramman R, Jain A: FK506 for liver, kidney, and pancreas transplantation. Lancet, II: 1000–1004, 1989.

    Article  Google Scholar 

  109. McCauley J, Tzakis AG, Fung JJ, Todo S, Starzl TE: FK506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet, 335: 674, 1990.

    Article  PubMed  CAS  Google Scholar 

  110. Zoja C, Benigni A, Verroust P, Ronco P, Bertani T, Remuzzi G: Indomethacin reduces proteinuria in passive Heymann nephritis in rats. Kidney Int, 31: 1335–1343, 1987.

    Article  PubMed  CAS  Google Scholar 

  111. Donker AJ, Brentjens JR, Van der Hem GK, Arisz L: Treatment of the nephrotic syndrome with indomethacin. Nephron, 22:, 1978.

    Google Scholar 

  112. Laurent J, Belghiti D, Bruneau C, Lagrue G: Diclofenac, a non-steroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study. Am J Nephrol, 7:198–202, 1987.

    Article  PubMed  CAS  Google Scholar 

  113. Lagrue G, Laurent J, Belghiti D: Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID). Int Urol Nephrol, 20: 669–677, 1988.

    Article  PubMed  CAS  Google Scholar 

  114. Woo KT, Chiang GS, Yap HK, Lim CH: Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies. Ann Acad Med Singapore, 17: 226–231, 1988.

    PubMed  CAS  Google Scholar 

  115. Shearman JD, Yin ZG, Aarons I, Smith PS, Woodroffe AJ, Clarkson AR: The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy. Clin Nephrol, 6: 320–329, 1988.

    Google Scholar 

  116. Soulillou JP, Peyronnet P, Le Mauff B, Hourmant M, Olive D, Mawas C, Delaage M, Him M, Jacques Y: Prevention of rejection of kidney transplants by monoclonal antibodies directed against interleukin 2. Lancet, I: 1339–1342, 1987.

    Article  Google Scholar 

  117. Strom TB, Kelley VE: Towards more selective therapies to block undesired immune responses. Kidney Int, 35: 1026–1033, 1989.

    Article  PubMed  CAS  Google Scholar 

  118. Wofsey D, Seaman WE: Reversal of advanced murine lupus in NZB/NZW Fl mice by treatment with monoclonal antibody to L3T4. J Immunol, 138: 3247–3253, 1987.

    Google Scholar 

  119. Mathieson PW, Cobbold SP, Hale G, Clark MJ, Oliveira DBG, Lockwood CM, Waldmann H: Monoclonal antibody therapy in systemic vasculitis. N Engl J Med, 1990 (in press).

    Google Scholar 

  120. Vandenbark AA, Hashim G, Offner H: Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune enecephalomyelitis. Nature, 341: 541–544, 1989.

    Article  PubMed  CAS  Google Scholar 

  121. Acha-Orbea H, Mitchell DJ, Timmerman L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L: Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell, 54: 263–273, 1988.

    Article  PubMed  CAS  Google Scholar 

  122. Patrono C, Ciabattoni G, Remuzzi G: Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest, 76: 1011–1018, 1985.

    Article  PubMed  CAS  Google Scholar 

  123. Kelley VE, Sneve S, Musinski S: Increased renal thromboxane production in murine lupus nephritis. J Clin Invest, 77: 252–259, 1986.

    Article  PubMed  CAS  Google Scholar 

  124. Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, Patrignani P, Ciabattoni G, Patrono C: Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med, 320: 421–425, 1989.

    Article  PubMed  CAS  Google Scholar 

  125. Kelley VE, Ferreti A, Izui A, Strom TB: A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol, 134: 1914–1919, 1985.

    PubMed  CAS  Google Scholar 

  126. Endres S, Ghorbani R, Kelley VE, Georgiles K, Lonnemann G, van der Meer JWM, Cannon JG, Rogers TS, Klempner MS, Weber PC, Schaefer EJ, Wolff SM, Dinarello CA: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med, 320: 265–271, 1989.

    Article  PubMed  CAS  Google Scholar 

  127. Prickett JD, Robinson DR, Steinberg AD: Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZBxNZW Fl mice. J Clin Invest, 68: 556–559, 1981.

    Article  PubMed  CAS  Google Scholar 

  128. Segal R, Fine LG: Polypeptide growth factors and the kidney. Kidney Int, 36 (Suppl 27): S2–S10, 1989.

    Google Scholar 

  129. Frampton G, Hildreth G, Hartley B, Cameron JS, Heldin CH, Wastson A: Could platelet-derived growth factor have a role in the pathogenesis of lupus nephritis?. Lancet, II: 343, 1988.

    Article  Google Scholar 

  130. Shinkai Y, Cameron JS: Trial of platelet-derived growth factor anatagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit. Br J Exp Pathol, 68: 847–852, 1987.

    PubMed  CAS  Google Scholar 

  131. Bowman C, Mason DW, Pusey CD, Lockwood CM: Autoregulation of autoantibody synthesis in mercuric chloride nephritis in the Brown Norway rat. I. A role for T suppressor cells. EUR J Immunol, 14: 464–470, 1984.

    CAS  Google Scholar 

  132. Chalopin JM, Lockwood CM: Autoregulation of autoantibody synthesis in mercuric chloride nephritis in the Brown Norway rat. II. Presence of antigen-augmentable plaque-forming cells in the spleen is associated with humoral factors behaving as auto-anti-idiotypic antibodies. Eur J Immunol, 14: 470–475, 1984.

    Article  PubMed  CAS  Google Scholar 

  133. Neilson EG, McCafferty E, Mann R, Michaud L, Clayman M: Tubular antigen-derivatized cells induce a disease-protective, antigen-specific, and idiotype-specific suppressor T cell network restricted by I-J and Igh-V in mice with experimental interstitial nephritis. J Exp Med, 162: 215–230, 1985.

    Article  PubMed  CAS  Google Scholar 

  134. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE: Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high dose intravenous gammaglobulin. Lancet, II: 765–768,1984.

    Article  Google Scholar 

  135. Imbach P, Barandun S, D'Apuzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet, I: 1228–1231, 1981.

    Article  Google Scholar 

  136. Jayne DRW, Rossi F, Kazatchkine MD, Lockwood CM: Anti-idiotypes against autoantibodies to neutrophil cytoplasmic antigens are present in pooled human immunoglobulin and post-recovery sera. 7th ICI, 273,1989.

    Google Scholar 

  137. Jayne DRW, Lockwood CM: Pathogenesis of acute Kawasaki disease (letter). Lancet, 335: 410–411, 1990.

    Article  PubMed  CAS  Google Scholar 

  138. Palla R, Bionda A, Marchitiello M: High-dose intravenous gammaglobulin for membranous nephropathy (letter). Clin Nephrol, 26: 314, 1986.

    PubMed  CAS  Google Scholar 

  139. Savage COS: Regulation of autoantibody production in man. The role of idiotype-antiidiotype network interactions in anti-glomerular basement membrane antibody mediated disease. PhD Thesis, University of London, 1986.

    Google Scholar 

  140. Clayman MD, Sun MJ, Michaud L, Brill-Dashoff J, Riblet R, Neilson EG: Clonotypic heterogeneity in experimental interstitial nephritis. Restricted specificity of the anti-tubular basement membrane B cell repertoire is associated with a disease-modifying crossreactive idiotype. J Exp Med, 167: 1296–1312, 1988.

    Article  PubMed  CAS  Google Scholar 

  141. Briggs WA, Johnson JP, Teichman S, Yeager HC, Wilson CB: Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture’s syndrome. Medicine, 58: 348–361, 1979.

    Article  PubMed  CAS  Google Scholar 

  142. Simpson U, Doak PB, Williams LC, Blacklock HA, Hill RS, Teague CA, Herdson PB, Wilson CB: Plasma exchange in Goodpasture’s syndrome. Am J Nephrol, 2: 301–311, 1982.

    Article  PubMed  CAS  Google Scholar 

  143. Johnson JP, Moore J Jr, Austin HA, Balow JE, Antonovych TT, Wilson CB: Therapy of antiglomerular basement membrane antibody mediated disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine, 64: 219–227, 1985.

    PubMed  CAS  Google Scholar 

  144. Walker RG, Scheinkestel C, Becker GJ, Owen JE, Dowling JP, Kincaid-Smith P: Clinical and morphological aspects of the management of crescentic antiglomerular basement membrane antibody (anti-GBM) nephritis. Q J Med, 54: 75–89, 1985.

    PubMed  CAS  Google Scholar 

  145. Brandwein S, Esdaile J, Danoff D, Tannenbaum H: Wegener’s granulomatosis. Clinical features and outcome in 13 patients. Arch Int Med, 143:476–479, 1983.

    CAS  Google Scholar 

  146. Littlejohn GO, Ryan PJ, Holdsworth SR: Wegener’s granulomatosis: clinical features and outcome in seventeen patients. Aust NZ J Med, 15: 241–245, 1985.

    Article  CAS  Google Scholar 

  147. Ten Berge IJ, Wilmink JM, Meyer CJ, Surachno J, ten Veen KH, Balk TG, Schellekens PT: Clinical and immunological follow-up of patients with severe renal disease in Wegener’s granulomatosis. Am J Nephrol, 5: 21–29, 1985.

    Article  PubMed  CAS  Google Scholar 

  148. Wilkowski MJ, Velosa JA, Holley KE, Offord KP, Chu C-P, Torres VE, McCarthy JT, Donadio JV Jr, Wagoner RD: Risk factors in idiopathic renal vasculitis and glomerulonephritis. Kidney Int, 36: 1133–1141, 1989.

    Article  PubMed  CAS  Google Scholar 

  149. Gaskin G, Bateson K, Evans DJ, Rees AJ, Pusey CD: Response to treatment and long-term follow-up in 60 patients with Wegener’s granulomatosis. Nephrol Dial Transplant, 4: 832–833, 1989.(Abstract)

    Google Scholar 

  150. Falk RJ, Hogan SL, Jennette SL: A prospective cohort study of 70 patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Kidney Int, 37: 256, 1990 (Abstract). 95

    Google Scholar 

  151. Row PG, Cameron JS, Turner DR, Evans DJ, White RHR, Ogg CS, Chantier C, Brown CB: Membranous nephropathy: long-term follow-up and association with neoplasia. Q J Med, 44: 207–239, 1975.

    PubMed  CAS  Google Scholar 

  152. Pierides AM, Malasit P, Morley AR, Wilkinson RW, Uldall PR, Kerr DNS: Idiopathic membranous nephropathy. Q J Med, 46: 163–177, 1977.

    PubMed  CAS  Google Scholar 

  153. Noel LH, Zanetti M, Droz D, Barbanel C: Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med, 66: 82–90, 1979.

    CAS  Google Scholar 

  154. Ramzy MH, Cameron JS, Turner DR, Neild GH, Ogg CS, Hicks J: The long-term outcome of idiopathic membranous nephropathy. Clin Nephrol, 16: 13–19, 1981.

    PubMed  CAS  Google Scholar 

  155. Davison AM, Cameron JS, Kerr DNS, Ogg CS, Wilkinson RW: The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol, 22: 61–67, 1984.

    PubMed  CAS  Google Scholar 

  156. Honkanen E: Survival in idiopathic membranous glomerulonephritis. Clin Nephrol, 25: 122–128, 1986.

    PubMed  CAS  Google Scholar 

  157. Kida H, Asamoto T, Yokoyama H, Tomosugi N, Hattori N: Long-term prognosis of membranous nephropathy. Clin Nephrol, 25: 64–69, 1986.

    PubMed  CAS  Google Scholar 

  158. MacTier R, Boulton-Jones JM, Payton CD, McLay A: The natural history of membranous nephropathy in the West of Scotland. Q J Med, 60: 793–802, 1986.

    PubMed  CAS  Google Scholar 

  159. Murphy BF, Fairley KF, Kincaid-Smith PS: Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. Clin Nephrol, 6: 175–181, 1988.

    Google Scholar 

  160. Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, Schumm G, Balz C, Gartner HV: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol, 31: 67–76, 1989.

    PubMed  CAS  Google Scholar 

  161. De Santo NG, Capodicasa G, Giordano C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin (letter). Am J Nephrol, 7: 74–76, 1987.

    Article  Google Scholar 

  162. Meyrier A, Simon P: Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis. Adv Nephrol, 17: 127–150, 1988.

    CAS  Google Scholar 

  163. Chan MK, Kwan SY, Chan KW, Yeung CK: Controlled trial of anti-platelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis, 9: 417–421, 1987.

    PubMed  CAS  Google Scholar 

  164. Lines DR, Coleman M, Gallus A: Focal glomerulosclerosis treated with heparin. Arch Dis Child, 64: 855–857, 1989.

    Article  PubMed  CAS  Google Scholar 

  165. Miura M, Endoh H, Nomoto Y, Sakai H: Long-term effect of urokinase therapy in IgA nephropathy. Clin Nephrol, 32: 209–216, 1989.

    PubMed  CAS  Google Scholar 

  166. Dohi K, Nakamoto Y, Ishikawa H: Mesangial proliferave glomerulonephritis. Natural history and effects of dextran sulfate. Jpn J Med, 26: 50–57, 1987.

    CAS  Google Scholar 

  167. Tomino Y, Yagame M, Watanabe S, Miura M, Suga T, Nomoto Y, Sakai H, Takeda M: Clinical effect of newly developed oral carbonaceous adsorbent (AST-120) in patients with advanced stages of chronic glomerulonephritis. Ann Acad Med Singapore, 16:163–166, 1987.

    PubMed  CAS  Google Scholar 

  168. Niwa T, Maeda K, Shibata M, Yamada K: Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome. Clin Nephrol, 30: 276–281, 1988.

    PubMed  CAS  Google Scholar 

  169. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): a two-year prospective trial. Clin Nephrol, 31: 128–131, 1989.

    PubMed  CAS  Google Scholar 

  170. Nagayama Y, Namura Y, Tamura T, Muso R: Beneficial effect of prostaglandin E1 in three cases of lupus nephritis with nephrotic syndrome. Ann Allergy, 61: 289–295, 1988.

    PubMed  CAS  Google Scholar 

  171. Tomino Y, Sakai H, Hanzawa S, Ohno J, Kitajima T, Sakai O: Clinical effect of danazol in patients with IgA nephropathy. Jpn J Med, 26: 162–166, 1987.

    Article  PubMed  CAS  Google Scholar 

  172. Savchenko NE, Levin VI, Pilotovich VS, Pivovarova IV, Fateeva NG: Passive immunotherapy using anti-HLA antibodies in the treatment of patients with nephrotic syndrome. Klin Med Mosk, 67: 67–70, 1989.

    PubMed  CAS  Google Scholar 

  173. Meifang C: Recent advances in the prophylaxis and treatment of chronic glomerulonephritis with combined TCM and WM. J Tradit Chin Med, 3: 151–162, 1983.

    Google Scholar 

  174. Wei M, Huang QF, Zeng SP, Lang ZW: Studies on treatment of glomerulonephritis by TCM yi-qi huo-xue methods. J Tradit Chin Med, 8: 55–60, 1988.

    PubMed  CAS  Google Scholar 

  175. Ratner ZG, Pyrig LA, Chumanskii LI, Savchenko IuK, Gerasimova ZS: Effectiveness of sanitorium treatment of patients with chronic glomerulonephritis depending on their permanent residence. Vrach Delo, 5: 72–75, 1989.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal Unit, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK

    Peter W. Mathieson

  2. University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge, UK

    Andrew J. Rees

Authors
  1. Peter W. Mathieson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Rees
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nephrology, University of Naples, Naples, Italy

    Vittorio E. Andreucci

  2. Division of Nephrology, UCLA School of Medicine, University of California, Los Angeles, California, USA

    Leon G. Fine

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Mathieson, P.W., Rees, A.J. (1990). Changing Views on the Treatment of Glomerulonephritis. In: Andreucci, V.E., Fine, L.G. (eds) International Yearbook of Nephrology 1991. International Yearbook of Nephrology 1991, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3946-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3946-9_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6761-1

  • Online ISBN: 978-1-4615-3946-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation